Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172799004> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W3172799004 endingPage "e21070" @default.
- W3172799004 startingPage "e21070" @default.
- W3172799004 abstract "e21070 Background: Treatment strategies for advanced lung squamous cell cancer (LSCC) of third-line or further-line are limited. We assessed the efficacy and safety of recombinant anti-EGFR monoclonal antibody SCT200 in patients with advanced LSCC in a phase 1b study. Methods: Advanced LSCC Patients previously treated with at least two chemotherapy regimens were randomly assigned to intravenous injection of SCT200 9 or 12 mg/kg every week (QW) for a maximum of 6 cycles, followed by 12 or 15 mg/kg every two weeks (Q2W). The primary endpoint was objective response rate (ORR). The secondary endpoint was progression free survival (PFS), overall survival (OS) and safety. This study was registered at ClinicalTrials.gov (NCT03808701). Results: Between March 19, 2019 and October 19, 2019, a total of 25 patients were enrolled and 23 were included in the final analysis (10 low dose [9mg/kg] and 13 high dose [12mg/kg]). The median age was 57 years old, and 21 (91.3%) patients were males. 22 patients (95.6%) had ECOG performance status of 1, and 17 (74%) were stage IV. The baseline characteristics were similar between the two dose groups. While no patients were evaluated as complete response or partial response, 5 and 6 patients achieved stable disease in the 9mg/kg and 12mg/kg dose groups respectively. However, the mOS was 5.96m (2.14 ̃ NR) and 9.59m (2.86 ̃ NR) in the low and high dose groups respectively. The mPFS was 2.23 (0.23 ̃ 5.26) and 1.38 (1.25 ̃ 3.02) in each group. The most common grade ≥3 treatment-related AEs were hypomagnesemia (13%), rash (13%) and anemia (4.3%). Conclusions: In this trial, a clinical benefit in OS was observed in the high dose group. SCT200 was shown to be safe and well tolerated in all patients. Our study indicated that SCT200 could serve as a potential single treatment or in combination with other therapy for advanced LSCC. Clinical trial information: NCT03808701. [Table: see text]" @default.
- W3172799004 created "2021-06-22" @default.
- W3172799004 creator A5022356244 @default.
- W3172799004 creator A5028631107 @default.
- W3172799004 creator A5077703494 @default.
- W3172799004 creator A5086270619 @default.
- W3172799004 date "2021-05-20" @default.
- W3172799004 modified "2023-10-17" @default.
- W3172799004 title "Efficacy and safety of anti-EGFR monoclonal antibody (SCT200) as third-line or further treatment in advanced lung squamous cell cancer." @default.
- W3172799004 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e21070" @default.
- W3172799004 hasPublicationYear "2021" @default.
- W3172799004 type Work @default.
- W3172799004 sameAs 3172799004 @default.
- W3172799004 citedByCount "0" @default.
- W3172799004 crossrefType "journal-article" @default.
- W3172799004 hasAuthorship W3172799004A5022356244 @default.
- W3172799004 hasAuthorship W3172799004A5028631107 @default.
- W3172799004 hasAuthorship W3172799004A5077703494 @default.
- W3172799004 hasAuthorship W3172799004A5086270619 @default.
- W3172799004 hasConcept C121608353 @default.
- W3172799004 hasConcept C126322002 @default.
- W3172799004 hasConcept C141071460 @default.
- W3172799004 hasConcept C143998085 @default.
- W3172799004 hasConcept C197934379 @default.
- W3172799004 hasConcept C203092338 @default.
- W3172799004 hasConcept C2776256026 @default.
- W3172799004 hasConcept C2776694085 @default.
- W3172799004 hasConcept C2778822529 @default.
- W3172799004 hasConcept C2779984678 @default.
- W3172799004 hasConcept C31760486 @default.
- W3172799004 hasConcept C535046627 @default.
- W3172799004 hasConcept C71924100 @default.
- W3172799004 hasConcept C90924648 @default.
- W3172799004 hasConceptScore W3172799004C121608353 @default.
- W3172799004 hasConceptScore W3172799004C126322002 @default.
- W3172799004 hasConceptScore W3172799004C141071460 @default.
- W3172799004 hasConceptScore W3172799004C143998085 @default.
- W3172799004 hasConceptScore W3172799004C197934379 @default.
- W3172799004 hasConceptScore W3172799004C203092338 @default.
- W3172799004 hasConceptScore W3172799004C2776256026 @default.
- W3172799004 hasConceptScore W3172799004C2776694085 @default.
- W3172799004 hasConceptScore W3172799004C2778822529 @default.
- W3172799004 hasConceptScore W3172799004C2779984678 @default.
- W3172799004 hasConceptScore W3172799004C31760486 @default.
- W3172799004 hasConceptScore W3172799004C535046627 @default.
- W3172799004 hasConceptScore W3172799004C71924100 @default.
- W3172799004 hasConceptScore W3172799004C90924648 @default.
- W3172799004 hasIssue "15_suppl" @default.
- W3172799004 hasLocation W31727990041 @default.
- W3172799004 hasOpenAccess W3172799004 @default.
- W3172799004 hasPrimaryLocation W31727990041 @default.
- W3172799004 hasRelatedWork W1544661582 @default.
- W3172799004 hasRelatedWork W2009096079 @default.
- W3172799004 hasRelatedWork W2085889668 @default.
- W3172799004 hasRelatedWork W2114684119 @default.
- W3172799004 hasRelatedWork W2569260518 @default.
- W3172799004 hasRelatedWork W2889701300 @default.
- W3172799004 hasRelatedWork W2931438826 @default.
- W3172799004 hasRelatedWork W2943367773 @default.
- W3172799004 hasRelatedWork W3010513424 @default.
- W3172799004 hasRelatedWork W3197516152 @default.
- W3172799004 hasVolume "39" @default.
- W3172799004 isParatext "false" @default.
- W3172799004 isRetracted "false" @default.
- W3172799004 magId "3172799004" @default.
- W3172799004 workType "article" @default.